|
1
|
Lupien M, Eeckhoute J, Meyer CA, Krum SA,
Rhodes DR, Liu XS and Brown M: Coactivator function defines the
active estrogen receptor alpha cistrome. Mol Cell Biol.
29:3413–3423. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Holz MK, Digilova A, Yamnik RL, Davis DC,
Murphy CJ and Brodt N: Estrogen receptor α is a target of mTOR/S6K1
signaling in control of breast cancer cell proliferation. Cancer
Res. 69 Suppl 2:S40622009. View Article : Google Scholar
|
|
3
|
Laws MJ, Das A, Li Q, et al: The Estrogen
Receptor Alpha Plays a Central Role in Controlling Stromal
Differentiation and Angiogenesis in the Mouse and Human Endometria
During Early Pregnancy. Meeting of the
Society-For-The-Study-Of-Reproduction. 55. 2009.https://doi.org/10.1093/biolreprod/81.s1.32
|
|
4
|
Sayeed A, Konduri SD, Liu W, Bansal S, Li
F and Das GM: Estrogen receptor α inhibits p53-mediated
transcriptional repression: Implications for the regulation of
apoptosis. Cancer Res. 67:7746–7755. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lewis JS and Jordan VC: Selective estrogen
receptor modulators (SERMs): Mechanisms of anticarcinogenesis and
drug resistance. Mutat Res. 591:247–263. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meijer D, van Agthoven T, Bosma PT, Nooter
K and Dorssers LC: Functional screen for genes responsible for
tamoxifen resistance in human breast cancer cells. Mol Cancer Res.
4:379–386. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ignatov A, Ignatov T, Roessner A, Costa SD
and Kalinski T: Role of GPR30 in the mechanisms of tamoxifen
resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat.
123:87–96. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng Y, Zhang J, Xu ZZ, Sheng JM, Zhang
XC, Wang HH, Teng XD, Liu XJ, Cao J and Teng LS: Quantitative
profiles of the mRNAs of ER-α and its novel variant ER-α36 in
breast cancers and matched normal tissues. J Zhejiang Univ Sci B.
11:144–150. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gu W, Dong N, Wang P, Shi C, Yang J and
Wang J: Tamoxifen resistance and metastasis of human breast cancer
cells were mediated by the membrane-associated estrogen receptor
ER-α36 signaling in vitro. Cell Biol Toxicol. 2016.
|
|
10
|
Liang J and Shang Y: Estrogen and cancer.
Annu Rev Physiol. 75:225–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee LMJ, Cao J, Deng H, Chen P, Gatalica Z
and Wang ZY: ER-α36, a novel variant of ER-α, is expressed in
ER-positive and -negative human breast carcinomas. Anticancer Res.
28:479–483. 2008.PubMed/NCBI
|
|
12
|
Rao J, Jiang X, Wang Y and Chen B:
Advances in the understanding of the structure and function of
ER-α36, a novel variant of human estrogen receptor-alpha. J Steroid
Biochem Mol Biol. 127:231–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin SL, Yan LY, Zhang XT, Yuan J, Li M,
Qiao J, Wang ZY and Sun QY: ER-alpha36, a variant of ER-alpha,
promotes tamoxifen agonist action in endometrial cancer cells via
the MAPK/ERK and PI3K/Akt pathways. PLoS One. 5:e90132010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang XT, Kang LG, Ding L, Vranic S,
Gatalica Z and Wang ZY: A positive feedback loop of ER-α36/EGFR
promotes malignant growth of ER-negative breast cancer cells.
Oncogene. 30:770–780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Ding L, Kang L and Wang ZY:
Estrogen receptor-alpha 36 mediates mitogenic antiestrogen
signaling in ER-negative breast cancer cells. PLoS One.
7:e301742012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J,
Wang T, Fan Z, Fan T, Lin B, et al: Expression of ER-{α}36, a novel
variant of estrogen receptor {α}, and resistance to tamoxifen
treatment in breast cancer. J Clin Oncol. 27:3423–3429. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Honma N, Horii R, Iwase T, Saji S, Younes
M, Takubo K, Matsuura M, Ito Y, Akiyama F and Sakamoto G: Clinical
importance of estrogen receptor-β evaluation in breast cancer
patients treated with adjuvant tamoxifen therapy. J Clin Oncol.
26:3727–3734. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Katsanis N, Yaspo ML and Fisher EMC:
Identification and mapping of a novel human gene, HRMT1L1,
homologous to the rat protein arginine N-methyltransferase 1
(PRMT1) gene. Mamm Genome. 8:526–529. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Scott HS, Antonarakis SE, Lalioti MD,
Rossier C, Silver PA and Henry MF: Identification and
characterization of two putative human arginine methyltransferases
(HRMT1L1 and HRMT1L2). Genomics. 48:330–340. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blythe SA, Cha SW, Tadjuidje E, Heasman J
and Klein PS: beta-Catenin primes organizer gene expression by
recruiting a histone H3 arginine 8 methyltransferase, Prmt2. Dev
Cell. 19:220–231. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Iwasaki H, Kovacic JC, Olive M, Beers JK,
Yoshimoto T, Crook MF, Tonelli LH and Nabel EG: Disruption of
protein arginine N-methyltransferase 2 regulates leptin
signaling and produces leanness in vivo through loss of STAT3
methylation. Circ Res. 107:992–1001. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yildirim AO, Bulau P, Zakrzewicz D,
Kitowska KE, Weissmann N, Grimminger F, Morty RE and Eickelberg O:
Increased protein arginine methylation in chronic hypoxia: Role of
protein arginine methyltransferases. Am J Respir Cell Mol Biol.
35:436–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ganesh L, Yoshimoto T, Moorthy NC, Akahata
W, Boehm M, Nabel EG and Nabel GJ: Protein methyltransferase 2
inhibits NF-kappaB function and promotes apoptosis. Mol Cell Biol.
26:3864–3874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhong J, Cao RX, Liu JH, Liu YB, Wang J,
Liu LP, Chen YJ, Yang J, Zhang QH, Wu Y, et al: Nuclear loss of
protein arginine N-methyltransferase 2 in breast carcinoma is
associated with tumor grade and overexpression of cyclin D1
protein. Oncogene. 33:5546–5558. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qi C, Chang J, Zhu Y, Yeldandi AV, Rao SM
and Zhu YJ: Identification of protein arginine methyltransferase 2
as a coactivator for estrogen receptor α. J Biol Chem.
277:28624–28630. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhong J, Cao RX, Zu XY, Hong T, Yang J,
Liu L, Xiao XH, Ding WJ, Zhao Q, Liu JH, et al: Identification and
characterization of novel spliced variants of PRMT2 in breast
carcinoma. FEBS J. 279:316–335. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shen Y, Shi X and Pan J: The
conformational control inhibitor of tyrosine kinases DCC-2036 is
effective for imatinib-resistant cells expressing T674I
FIP1L1-PDGFRα. PLoS One. 8:e730592013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shen Y, Ren X, Ding K, Zhang Z, Wang D and
Pan J: Antitumor activity of S116836, a novel tyrosine kinase
inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing
cells. Oncotarget. 5:10407–10420. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Herrmann F, Pably P, Eckerich C, Bedford
MT and Fackelmayer FO: Human protein arginine methyltransferases in
vivo - distinct properties of eight canonical members of the PRMT
family. J Cell Sci. 122:667–677. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Frankel A, Yadav N, Lee J, Branscombe TL,
Clarke S and Bedford MT: The novel human protein arginine
N-methyltransferase PRMT6 is a nuclear enzyme displaying unique
substrate specificity. J Biol Chem. 277:3537–3543. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kzhyshkowska J, Schütt H, Liss M, Kremmer
E, Stauber R, Wolf H and Dobner T: Heterogeneous nuclear
ribonucleoprotein E1B-AP5 is methylated in its Arg-Gly-Gly (RGG)
box and interacts with human arginine methyltransferase HRMT1L1.
Biochem J. 358:305–314. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY,
Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, et al: Antiestrogen
resistance in breast cancer and the role of estrogen receptor
signaling. Oncogene. 22:7316–7339. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jacquemier JD, Hassoun J, Torrente M and
Martin PM: Distribution of estrogen and progesterone receptors in
healthy tissue adjacent to breast lesions at various stages -
immunohistochemical study of 107 cases. Breast Cancer Res Treat.
15:109–117. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Clarke R, Leonessa F, Welch JN and Skaar
TC: Cellular and molecular pharmacology of antiestrogen action and
resistance. Pharmacol Rev. 53:25–71. 2001.PubMed/NCBI
|
|
35
|
Dontu G, Abdallah WM, Foley JM, Jackson
KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells.
Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Piva M, Domenici G, Iriondo O, Rábano M,
Simões BM, Comaills V, Barredo I, López-Ruiz JA, Zabalza I, Kypta
R, et al: Sox2 promotes tamoxifen resistance in breast cancer
cells. EMBO Mol Med. 6:66–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
